Thomas F. Murray
Curriculum Vitae Thomas F. Murray, Ph.D.
Education:
1971—B.S. (Biology), University of North Texas, Denton, Texas
1979—Ph.D. (Pharmacology), School of Medicine, University of Washington, Seattle, Washington
Brief Chronology of Employment:
1971—1973 Biology Teacher, Onondaga Central School, Nedrow, New York
1974—1976 Teaching Assistant, College of Pharmacy, Washington State University, Pullman, Washington
1976—1979 Research Assistant, Department of Pharmacology, University of Washington, Seattle, Washington (Major Professor: Akira Horita)
1979—1981 Pharmacology Research Associate, Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, D.C. (Preceptor: Erminio Costa)
1981—1983 Assistant Professor of Pharmacology, College of Pharmacy, Washington State University, Pullman, Washington
1983—1986 Assistant Professor of Pharmacology, College of Pharmacy, Oregon State University, Corvallis, Oregon
1986—1990 Associate Professor of Pharmacology, College of Pharmacy, Oregon State University, Corvallis, Oregon
1990—1997 Professor of Pharmacology, College of Pharmacy, Oregon State University, Corvallis, Oregon
1997—2006 Professor and Head, Department of Physiology and Pharmacology, College of Veterinary Medicine, the University of Georgia, Athens, Georgia
2006— Professor and Chair, Department of Pharmacology, Creighton University School of Medicine, Omaha, Nebraska
2008— Associate Dean for Research, Creighton University School of Medicine, Omaha, Nebraska
Societies:
Sigma Xi Rho Chi Phi Kappa Phi Society for Neuroscience American Society for Pharmacology and Experimental Therapeutics Society of Toxicology Phi Zeta
1 Thomas F. Murray
Professional Honors and Appointments:
1976—1979 National Institute on Drug Abuse Predoctoral Fellowship
1979—1981 National Institute of General Medical Sciences Pharmacology Research Associate Training Fellowship
1990 Ad hoc Member, National Institute on Drug Abuse Biomedical Review Research Committee
1990 Ad hoc Member, National Institute on Drug Abuse Special Review Committee Designer Drug Induced Neuropathology
1993 Ad hoc Member, National Institute on Drug Abuse Special Review Committee
1990—1994 Member, National Institute on Drug Abuse – Biomedical Research Review Committee
1994 Ad hoc Member, National Institute on Drug Abuse Special Review Committee – Human Basic and Clinical Neuroscience of Drug Addiction
1993—1997 Member, American Heart Association-Oregon/Washington Affiliate, Research Peer Review Committee
2000—2002 Ad hoc Member, NIH Integrative, Functional and Cognitive Neuroscience Committee
2001—2007 Distinguished Research Professor, the University of Georgia
2004—2007 Ad hoc Member, NIDA-K Training and Career Development Review Committee
2007—2011 Member, NIDA-K Training and Career Development Review Committee
2008---2009 Ad hoc Member, NIH, Brain Disorders and Related Neuroscience Fellowships Review Committee
University Committees Chaired:
1988—1990 Radiation Safety Committee Oregon State University
1989—1993 Graduate Studies and Research Committee College of Pharmacy Oregon State University
1991 Pharmacology Search Committee College of Pharmacy Oregon State University
1992 Pharmacology Search Committee College of Pharmacy Oregon State University
1992—1993 Space Utilization and Planning Committee College of Pharmacy Oregon State University
1994 Toxicology Program Chair Search Committee Oregon State University
1995—1997 Faculty Senate Library Committee Oregon State University
1995—1997 Tenure and Promotion Committee College of Pharmacy Oregon State University
2 Thomas F. Murray
1998 Chair, Ad hoc Committee for Budgeted College of Veterinary Medicine Assignment of Time Policy The University of Georgia
2001 Chair, Department of Medical Microbiology College of Veterinary Medicine And Parasitology Headship Search Committee The University of Georgia
2004 Chair, Long Range Planning College of Veterinary Medicine and Facilities Committee The University of Georgia
2005 External Reviewer College of Veterinary Medicine Department of Biomedical Sciences Iowa State University
2005 Chair, External Review Committee East Carolina University Department of Pharmacology Brody School of Medicine
1997—2006 Head College of Veterinary Medicine Department of Physiology and Pharmacology The University of Georgia
2004—2006 Member, Research Advisory Council The University of Georgia Office of the Vice President for Research
2006—present Member, Financial Advisory Committee Creighton University School of Medicine
2006—present Member, Leadership Council Creighton University School of Medicine
2006—present Member, Executive Committee Creighton University School of Medicine
2006—2008 Member, Research Planning Committee Creighton University School of Medicine
2007—present Member, IACUC Creighton University
2008—present Associate Dean for Research Creighton University School of Medicine
Invited Lectureships:
1. National Drug Abuse Conference, Seattle, WA, April, 1978. “Behavioral Pharmacology of Phencyclidine.”
2. National Institute on Drug Abuse Research Fellows Conference, Washington, D.C. August, 1979. “Cholinergic Influences on the Pharmacological Effects of Δ9-THC.”
3. Joint French-U.S. Seminar on the Chemistry, Pharmacology, Toxicology, Therapy and Drug Abuse Aspects of Arylcyclohexylamines, LaGrande Motte, France, September 20–24, 1982. “Acute and Chronic Effects of Phencyclidine on Cholinergic Dynamics in Various Rat Brain Structures.”
4. Seminar entitled “Modulation of Cholinergic Dynamics in Rat Brain by Intracerebroventricular Administration of Adenosine Analogs”, at the Department of Pharmacology, School of Medicine, Oregon Health Sciences University, Portland, Oregon, March 15, 1983.
5. Collegium Internationale Neuropsychopharmacologicum, Symposium on “Adenosine Receptors and Methylxanthines in the CNS,” Florence, Italy, June 19–23, 1984. “Adenosine Receptor Mediated Modulation of Seizure Threshold in the Rat.”
3 Thomas F. Murray
6. Seminar entitled “Purinergic Modulation of Transmitter Dynamics and Seizure Threshold”, at the Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, Washington, November 9, 1984.
7. Third Workshop on Neurotransmitters in Epilepsy, Soverato, Italy, September 17–19, 1985. “A1 Adenosine Receptor Mediated Modulation of Seizure Threshold.”
8. Seminar entitled “Muscarinic Cholinergic Receptor in Marine Invertebrates: Implications for Learning”, at the Department of Medical Psychology, University of Calgary, Calgary, Alberta, Canada, February 27, 1986.
9. American Chemical Society Symposium on Bioactive Mechanisms: Proof, SAR and Prediction, Los Angeles, California, September 28, 1988. “A1 Adenosine Receptors in Heart: Functional and Biochemical Consequences of Activation.”
10. Fourth Workshop on Neurotransmitters in Epilepsy, Stresa, Italy, October 9–12, 1988. “A1 Adenosine Receptors Express Anticonvulsant Activity in Rat Prepiriform Cortex.”
11. Symposium on “Pharmacology, Biochemistry and Function of Adenosine Receptors” at 32nd Annual Meeting of the Western Pharmacology Society, Breckenridge, CO., January 1989 (Organizer and Chair).
12. Seminar entitled “Biochemical and Functional Characterization of A1 Adenosine Receptors” at the Department of Pharmacology, University of Alberta, Edmonton, Calgary, July 7, 1989.
13. Purine Nucleosides and Nucleotides in Cell Signaling: Targets for New Drugs, Rockville, M.D., September 17–20, 1989. “Agonist and Antagonist Radioligand Interactions with the Solubilized Porcine Atrial A1 Adenosine Receptor.”
14. Fourth International Symposium on Adenosine and Adenine Nucleotides, Lake Yamanaka, Japan, May 13– 17, 1990. “Biochemical and Pharmacological Characterization of A1 Adenosine Receptors.”
15. French-U.S. Joint Seminar on Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Protection? La Grande Motte, France, September 15–19, 1991. “High Affinity [3H]Dextrorphan Recognition Site of the NMDA Operated Cation Channel Mediates the Anticonvulsant Actions of Dextrorotatory Opioids and Phencyclidine.
16. Seminar entitled “Endogenous Adenosine as an Anticonvulsant” at the Department of Pharmacology, School of Medicine, University of Nevada Reno, March 5, 1992.
17. Seminar entitled “Manipulation of Endogenous Adenosine Affects Seizure Susceptibility” at Abbott Laboratories, Abbot Park, Illinois, August 27, 1992.
18. Fifth International Symposium on Adenosine and Adenine Nucleotides, Philadelphia, PA, May 9–13, 1994. “P2 Purinoceptor Agonists Elicit Behavioral Seizures in the Rat Prepiriform Cortex.”
19. Eighth International Symposium on Purine and Pyrimidine Metabolism, Bloomington, ID, May 1994. “Pathways of Adenosine Formation, Metabolism and Transport as Targets for Modulation of Seizure Susceptibility.
20. Seminar entitled, “Dextrorotatory Opioid Interaction with NMDA Receptors: What Can Dextromethorphan Do for You” at the School of Pharmacy, University of Montana, Missoula, MT, March 14, 1997.
21. Gordon Research Conference on Mycotoxins and Phycotoxins, Plymouth, NH, June 20-24, 1999. “Brevetoxin Induction of Neurotoxicity in Cultured Cerebellar Granule Cells.”
4 Thomas F. Murray
22. Seminar entitled, “NMDA Receptors as Molecular Targets for Marine Biotoxins and Dextrorotatory Opioids” at the Department of Pharmacology, University of Washington School of Medicine, Seattle, WA, June 11, 2001.
23. Seminar entitled “NMDA Receptors as Molecular Targets for Dextrorotatory Opioids” at the Department of Physiology and Neuroscience, Medical University of South Caroline, Charleston, SC, October 19, 2001.
24. Seminar entitled “On the Pharmacology of Roboing: NMDA Receptors as Targets for Dextrorotatory Opioids” at the Department of Pharmacology, Medical College of Georgia, Augusta, GA, March 15, 2002.
25. Seminar entitled “Autocrine Excitotoxicity: Common Sequalae of Marine Neurotoxin Exposure” at the Lovelace Respiratory Research Institute, Albuquerque, New Mexico, April 17, 2002.
26. Seminar entitled “Using FLIPR with Fluo-3 and Calcein AM to Characterize AMPA/Kainate Receptors in Cerebrocortical Neurons” at the 2003 International Drug Discovery Product Users Meeting, Half Moon Bay, CA, May 20, 2003.
27. Gordon Research Conference on Mycotoxins and Phycotoxins, Waterville, ME, June 15-20, 2003. “Convergence of Sodium Channel Activator (Brevetoxin) and NMDA Receptor Signaling in Cerebrocortical Neurons.”
28. Seminar entitled “Neurotoxins from Marine Algae and Cyanobacteria” at Marine-Freshwater Biomedical Sciences Center, Oregon State University, Corvallis, OR, May 9, 2003.
29. Seminar entitled “Convergence of Voltage-Gated Sodium Channel and NMDA Receptor Signaling in Cerebrocortical Neurons” at the Neuro-Psychiatric Institute, University of Illinois at Chicago, Chicago, IL, July 7, 2005.
30. American Society of Pharmacognosy, Corvallis, OR, July 23-27, 2005. “Discovery and Mechanisms of Neuroactive Marine Natural Products: A Tale of High Throughput Screening and Neurons.”
31. Seminar entitled “Convergence of Voltage-Gated Sodium Channel and NMDA Receptor Signaling in Cerebrocortical Neurons” at the Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE, October 11, 2005.
32. Aquatic Animal Models of Human Disease Conference, Athens, GA, October 30 – November 2, 2005, “Discovery and Mechanistic Characterization of Neuroactive Marine Natural Products.”
33. Ion Channel Targets, Boston MA, September 10, 2007, “Evaluating Ion Channel Mechanisms in Murine Neuronal Cultures and Human Embryonic Stem Cell-Derived Neurons Using FLIPR and Flex Station.”
34. Seminar entitled “Neuronal responses to voltage-gated sodium channel activators: From neurotoxicity to dendritic development” at the Department of Neuroscience, Medical University of South Carolina, Charleston, SC, September 21,2007.
35. Seminar entitled “Marine natural products as sodium channel gating modifiers: Neurotoxicants or novel therapeutics?” at Scripps Institution of Oceanography, University of California at San Diego, November 5, 2007.
36. Seminar entitled “Neuronal responses to sodium channel gating modifiers: From neurotoxicity to dendritogenesis” at the Barrow Neurological Institute, Phoenix, AZ, May 20, 2008.
37. Ion Channel Targets, San Francisco, CA, September 9-10, 2008, “Influence of lipid soluble gating modifier toxins on sodium influx in neocortical neurons.”
5 Thomas F. Murray
38. Seminar entitled “Neuronal responses to sodium channel gating modifiers: From neurotoxicity to neuritogenesis” at the College of Veterinary Medicine of Iowa State University, Ames, IA, September 18, 2008.
39. Seminar entitled “ Drug discovery strategies and high throughput screening in an academic environment” at Galleon Pharmaceuticals, Wayne, PA, September 30, 2008.
40. Seminar entitled “Discovery and Characterization of neuroactive marine natural products: voltage-gated sodium channels as a common target” at the School of Pharmacy, University of Mississippi, Oxford, MS, February 17, 2009.
41. Seminar entitled “Endogenous adenosine as an anticonvulsant” at Merck & Co., Inc, Baltimore, MD, May 8, 2009.
42. Target Discovery World Congress, San Francisco, CA, August 4-5, 2009, “Sodium channel activation augments NMDA receptor function and promotes neurite outgrowth in cerebrocortical neurons.”
Editorial Responsibilities:
Member of the Editorial Advisory Board of Neuropharmacology, 1986—1992
Review Manuscripts for: European Journal of Pharmacology Neuropharmacology Neuroscience Psychopharmacology Journal of Pharmacology and Experimental Therapeutics Molecular Pharmacology In Vitro Journal of Neurochemistry
Editor-in-Chief, Critical Reviews in Neurobiology, 2003—2007
Graduate Students and Postdoctoral Fellows Trained:
Past Predoctoral Trainees Year Dissertation Title Current Position Patricia Szot, Ph.D. 1987 Adenosine Receptor Research Associate, Dept. of Modulation of Seizure Psychiatry and Behavioral Susceptibility in Rats Sciences, University of Washington, Seattle, WA
Leslie Devaud, Ph.D. 1988 Pyrethroid Interaction with Associate Professor, College Peripheral-Type of Pharmacy, Idaho State Univ., Benzodiazepine Receptor Pocatello, ID
Mark Leid, Ph.D. 1989 Pharmacological Professor, College Characterization of the of Pharmacy, Oregon State Porcine Atrial A1 Adenosine University, Corvallis, OR Receptor
Amy J. Eshleman, Ph.D. 1990 Interaction of Pyrethroids Research Associate, and GABAA Receptor of VAMC, Portland, OR Trout Brain
6 Thomas F. Murray
Past Predoctoral Trainees Year Dissertation Title Current Position Ann T. Blair, Ph.D. 1990 Ontogeny of Adenosine Instructor, Mood Hood Community Mediated Negative College, OR Chronotropy in Embryonic Chick Heart
Ge Zhang, Ph.D. 1992 Activation of Adenosine Senior Research Scientist, Receptors in Prepiriform CNS Diseases Research Cortex Modulates Seizure DuPont Pharmaceuticals Co., Susceptibility Wilmington, DE
Jane Roth, Ph.D. 1995 Interaction of Dextrorphan Associate Professor, College with the N-Methyl-D- of Pharmacy, Oregon State Asparate Receptor University, Corvallis, OR
Xiaogin S. Zhao, M.S. 1995 Purine Nucleotide-induced Senior Staff Scientist, Seizures in Rat Prepiriform Rhone-Poulenec, Inc., Cortex Research Triangle, NC Frederick W. Berman, 1997 Development and Director, Toxicology Information D.V.M., Ph.D. Characterization of a Model Center, CROET Oregon Health of Glutamate and Domoate Science University, Portland, OR Toxicity in Cultured Cerebellar Granule Cells Barbara Hettinger, M.D. 1997 Regulation of Neuronal A1 Resident Ph.D. Adenosine Receptors Department of Internal Medicine Oregon Health Sciences Univ. Portland, OR
Ken Soderstrom, Ph.D. 1998 Characterization of an Associate Professor, Department of Amphibian Cannabinoid Pharmacology, East Carolina Receptor School of Medicine, Greenville, NC
Shashank Dravid, Ph.D. 1999— Brevetoxin-induced Assistant Professor of 2003 Modulation of Ca2+ Pharmacology Dynamics and NMDA School of Medicine Receptor Signaling in Creighton University Neurons Omaha, NE
Michael Moulton, MS, 1999— Indirect Excitotoxic Actions Dentist, DDS 2002 of Antillatoxin in Cerebellar Augusta, GA Granule Neurons
Christopher Brandon, Ph.D. 2000— Cloning and Assistant Professor of Biology 2004 Pharmacological East Georgia College Characterization of the Swainsboro, GA Equine Adenosine A2A and A3 Receptors: Potential Therapeutic Targets for the Treatment of Equine Endotoxemia
7 Thomas F. Murray
Past Predoctoral Trainees Year Dissertation Title Current Position Jennifer Peterson, MS 2003— Functional Characterization DVM Student 2005 of Brevetoxin Actions in College of Veterinary Medicine Neurons using Membrane The University of Georgia Potential-Sensitive Dyes Joju George 2004— present
Jabba 2006— present
Postdoctoral Trainees Training Period Current Position Paul H. Franklin, Ph.D. 1986—1992 Assistant Professor, College of Pharmacy, Oregon State Univ., Corvallis, OR
Frederick W. Berman, D.V.M., Ph.D. 1997—2000 Director Toxicology Information Center, Oregon Health Sciences University Portland, OR
Keith LePage, Ph.D. 1998—2006 Assistant Professor, Xavier University of New Orleans Cheryl Miller, Ph.D. 2001—2002 Staff Scientist, Hill’s Pet Nutrition Inc., Topeka, KA Xiu-Zhen Yan, M.D. 2002—2006 Research Associate, University of Georgia Zhengyu Cao, Ph.D. 2004—present Lakshmi Kelamangalath, Ph.D. 2009—present
Publications:
1. Murray, T.F., and Craigmill, A.L.: Interactions between 9-tetrahydrocannabinol and phencyclidine in rats and mice. Proc. of the Western Pharmacol. Soc. 19, 362–368, 1976.
2. Murray, T.F., Craigmill, A.L., and Fischer, G.F.: Pharmacological and behavioral components of tolerance to LSD and mescaline in rats. Pharmacol. Biochem. and Behav. 7, 239–244, 1977.
3. Murray, T.F.: The effects of phencyclidine on operant behavior in the rat: Biphasic effect and tolerance development. Life Sci., 22, 195–202, 1978.
4. Murray, T.F., and Horita, A.: Dose response effects of phencyclidine on stereotyped behavior in rats and antagonism by neuroleptics. Life Sci., 24, 2217–2226, 1979.
5. Murray, T.F., and Horita, A.: Effects of monoamine oxidase inhibitors on phencyclidine induced stereotyped behavior and brain levels in rats. Proc. of the Western Pharmacol. Soc. 22, 145–147, 1979.
6. Murray, T.F., and Cheney, D.L.: The effect of phencyclidine on the turnover rate of acetylcholine in various regions of rat brain. J. Pharmacol. Exp. Ther., 217, 733–737, 1981.
8 Thomas F. Murray
7. Costa, E., Cheney, D.L., and Murray, T.F.: Levonantradol–induced inhibition of acetylcholine turnover in rat hippocampus and striatum. J. Clin. Pharmacol. 21, 256–261, 1981.
8. Murray, T.F., and Cheney, D.L.: Localization of N6-cyclohexyl [3H] adenosine binding sites in rat and guinea pig brain. Neuropharmacology, 21, 575–580, 1982.
9. Murray, T.F., Blaker, W.D., Cheney, D.L. and Costa, E.: Inhibition of acetylcholine turnover rate in rat hippocampus and cortex by intraventricular injection of adenosine analogs. J. Pharmacol. Exp. Ther. 222, 550–555, 1982.
10. Murray, T.F.: Up-regulation of cortical adenosine receptors following chronic theophylline administration. Eur. J. Pharmacol., 82, 113–114, 1982.
11. Murray, T.F., McGill, W., and Cheney, D.L.: A comparison of the analgesic activities of 4, 5, 6, 7- tetrahydroisoxazolo[5, 4-c]-pyridin-3-al (THIP) and 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212). Eur. J. Pharmacol., 90, 179–184, 1983.
12. Murray, T.F., DeBarrows, B.R., Prieur, D.J. and Meyers, K.M.: [3H]-Imipramine binding in Fawnhooded rats. Neuropharmacology, 22, 781–784, 1983.
13. Murray, T.F.: A comparison of phencyclidine with other psychoactive drugs on cholinergic dynamics in the rat brain. In “Phencyclidine and Related Arylcyclohexylamines,” Eds. J.M. Kamenka, E.F. Domino and P. Geneste, NRP Books, Ann Arbor, MI., pp. 547–561, 1983.
14. Murray, T.F., Revuelta, A., Cheney, D.L., and Costa, E.: Modulation of Cholinergic Dynamics in the Rat Brain by 9-Tetrahydrocannabinol and Levonantradol. In “Dynamics of Neurotransmitter Function,” edited by I. Hanin, Raven Press, New York, pp. 81–89, 1984.
15. Murray, T.F. and Leid, M.E.: Interaction of dextrorotatory opioids with phencyclidine recognition sites in rat brain membranes. Life Sci., 34, 1899–1911, 1984.
16. Zobrist, R.H., Komiskey, H.L., Murray, T.F., and Hayton, W.L.: Aging: Effect on -carboline binding in hippocampal subfields. Neurobiology of Aging, 5, 49–53, 1984.
17. Murray, T.F., Sylvester, D., Schultz, C.S., and Szot, P.: Adenosine receptor mediated modulation of seizure threshold in the rat. Clinical Neuropharmacology, 7, 420–421, 1984.
18. Choromanski, J.M., Murray, T.F. and Weber, L.J.: Responses of the isolated buffalo sculpin heart to stabilized venom of the lionfish (Pterois volitans). Proc. West. Pharmacol. Soc., 27, 229–232, 1984.
19. Murray, T.F., Sylvester, D., Schultz, C.S. and Szot, P.: Purinergic modulation of pentylenetetrazol seizure threshold in the rat. Neuropharmacology, 24, 761–766, 1985.
20. Murray, T.F., Mpitsos, G., Siebenaller, J.F. and Barker, D.L.: Stereoselective L-[3H]QNB binding sites in nervous tissue of Aplysia californica: Evidence for muscarinic receptors. J. of Neuroscience, 5, 3184– 3188, 1985.
21. Barker, D.L., Murray, T.F., Siebenaller, J.F. and Mpitsos, G.J.: Characterization of muscarinic cholinergic receptors in the crab nervous system. J. of Neurochemistry. 46, 583–588, 1986.
22. Murray, T.F. and Szot, P.: A1 adenosine receptor mediated modulation of seizure susceptibility. In “Neurotransmitters in Epilepsy,” edited by P.L. Morselli, K.G. Lloyd, R.G. Fariello and J. Engel, Jr., Raven Press, New York, pp. 341–353, 1986.
23. Devaud, L.L., Szot, P. and Murray, T.F.: PK 11195 antagonism of pyrethroid-induced proconvulsant activity, Eur. J. Pharmacol., 120, 269–273, 1986.
9 Thomas F. Murray
24. Siebenaller, J.F. and Murray, T.F.: Phylogenetic distribution of [3H]cyclohexyladenosine binding sites in nervous tissue. Biochem. Biophys. Res. Comm., 137, 182–189, 1986.
25. Szot, P., Sanders, R.C. and Murray, T.F.: Theophylline-induced upregulation of A1 adenosine receptors associated with reduced sensitivity to chemoconvulsants. Neuropharmacology, 26, 1173–1180, 1987.
26. Murray, T.F., and Siebenaller, J.F.: Comparison of the binding properties of A1 adenosine receptors in brain membranes of two congeneric marine fishes living at different depths. J. of Comp. Physiol. B, 157, 267–277, 1987.
27. Leid, M., Franklin, P.H. and Murray, T.F.: Labeling of A1 adenosine receptors in porcine atria with the antagonist radioligand 8-cyclopentyl-1, 3[3H]dipropylxanthine. Eur. J. Pharmacol., 147, 141–144, 1988.
28. Sanders, R.C. and Murray, T.F.: Chronic theophylline exposure increases agonist and antagonist binding to A1 adenosine receptors in rat brain. Neuropharmacology, 27, 757–760, 1988.
29. Franklin, P.H., Tripp, E.D., Zhang, G., Gale, K. and Murray, T.F.: Adenosine receptor activation blocks seizures induced by bicuculline methiodide in the rat prepiriform cortex. Eur. J. Pharmacol., 150, 207–209, 1988.
30. Devaud, L.L. and Murray, T.F.: Involvement of peripheral type benzodiazepine receptors in the proconvulsant actions of pyrethroid insecticides. J. Pharmacol. Exp. Ther., 247, 14–22, 1988.
31. Leid, M., Schimerlik, M.I. and Murray, T.F.: Characterization of agonist radioligand interactions with porcine atrial A1 adenosine receptors. Mol. Pharmacol., 34, 334–339, 1988.
32. Mpitsos, G.J., Murray, T.F., Creech, H.C. and Barker, D.L.: Muscarinic action in one-trial Pavlovian conditioning: Scopolamine enhances experimental-control differences in the mollusc Pleurobranchaea. Brain Res. Bull., 21, 169–179, 1988.
33. Murray, T.F., and Mpitsos, G.J.: Evidence for heterogeneity of muscarinic receptors in the mollusc Pleurobranchaea. Brain Res. Bull., 21, 181–190, 1988.
34. Gale, K., Zhong, P., Miller, L.P. and Murray, T.F.: A crucial role for excitatory amino acids in the initiation and control of convulsions elicited from Area Tempastas. In “Frontiers in Excitatory Amino Acid Research,” Neurology and Neurobiology, Vol. 46, Liss, New York, pp. 211–218, 1988.
35. Leid, M., Schimerlik, M.I. and Murray, T.F.: Agonist radioligand interactions with the solubilized porcine atrial A1 adenosine receptor. Mol. Pharmacol. 35, 450–457, 1989.
36. Blair, T.A., Parenti, M. and Murray, T.F.: Development of physiological sensitivity to adenosine analogs in embryonic chick heart: Role of A1 adenosine receptors and adenylyl cyclase inhibition. Mol. Pharmacol., 35, 661–670, 1989.
37. Siebenaller, J.F. and Murray, T.F.: Evolutionary temperature adaptation of agonist binding to the A1 adenosine receptor. Biological Bulletin, 175, 410–416, 1988.
38. Eshleman, A.J. and Murray, T.F.: Differential binding properties of the peripheral-type benzodiazepine ligands, [3H]PK11195 and [3H]Ro5-4864, in trout and mouse brain membranes. J. Neurochemistry, 53, 494–502, 1989.
39. Sanders, R.C. and Murray, T.F.: Temporal relationship between A1 adenosine receptor upregulation and alterations in seizure susceptibility in rats. Neurosci. Letters, 101, 325–330, 1989.
10 Thomas F. Murray
40. Murray, T.F., Blair, T.A., Leid, M., Franklin, P.H. and Siebenaller, J.F.: A1 adenosine receptors in heart: Functional and biochemical consequences of activation. In “Probing Bioactive Mechanisms,” edited by P. Magee, J. Block and D. Henry, ACS Symposium Series, American Chemical Society, Washington, D.C., pp. 232–242, 1989.
41. Franklin, P.H., Zhang, G., Tripp, E.D. and Murray, T.F.: Adenosine A1 receptor activation mediates suppression of (-)-bicuculline methiodide-induced seizures in rat prepiriform cortex. J. Pharmacol. Exp. Ther., 251, 1229–1236, 1989.
42. Siebenaller, J.F. and Murray, T.F.: A1 adenosine receptor modulation of adenylyl cyclase of a deep-living teleost fish, Antimora rostrata. Biological Bulletin, 178, 65–73, 1990.
43. Leid, M., Franklin, P.H. and Murray, T.F.: Antagonist radioligand binding to solubilized porcine atrial A1 adenosine receptors. In “Purine Nucleosides and Nucleotides in Cell Signaling: Targets for New Drugs,” edited by K.A. Jacobsen, J.W. Daly and V. Manganiello, Springer, New York, 73–77, 1990.
44. Eshleman, A.J. and Murray, T.F.: GABA dependence of pyrethroid and Ro5-4864 modulation of [35S]TBPS binding in piscine brain. Neuropharmacology, 26, 641–648, 1990.
45. Zhang, G., Franklin, P.H. and Murray, T.F.: Anticonvulsant effect of N-ethylcarboxamido-adenosine against kainic acid-induced seizures in the rat prepiriform cortex. Neurosci. Letters, 114, 345–350, 1990.
46. Franklin, P.H. and Murray, T.F.: Identification and initial characterization of high affinity [3H]dextrorphan binding sites in rat brain. Eur. J. Pharmacol.-Molecular Pharmacol. Section, 189, 89–93, 1990.
47. Deviche, P., Murray, T.F. and Moore, F.C.: Effects of sodium and temperature on naloxone binding in brain tissues of a urodele amphibian. Comparative Biochemistry and Physiology, Part C, 96, 393–398, 1990.
48. Steketee, J. D., Striplin, C.D., Murray, T.F. and Kalivas, P.W.: Possible role for G-proteins in behavioral sensitization to cocaine. Brain Res., 545, 287–291, 1991.
49. Eshleman, A.J. and Murray, T.F.: Pyrethroid insecticides indirectly inhibit GABA-dependent 36Cl- influx in trout brain synaptoneurosomes. Neuropharmacology, 30, 1333–1341, 1991.
50. Murray, T.F., Leid, M. and Schimerlik, M.I.: Solubilization of A1 adenosine receptors from porcine atrial membranes. In “Role of Adenosine and Adenosine Nucleotides in the Biological System.” Edited by S. Imai and M. Nakazawa, Elsevier, Amsterdam, 81–90, 1991.
51. Siebenaller, J.F. and Murray, T.F.: The effects of hydrostatic pressure on A1 adenosine receptor signal transduction in brain membranes of two congeneric marine fishes. J. of Exptl. Biol., 159, 23–43, 1991.
52. Orchinik, M., Murray, T.F. and Moore, F.L.: A corticosteroid receptor in neuronal membranes. Science, 252, 1848–1851, 1991.
53. Orchinik, M., Murray, T.F. and Moore, F.L.: Corticosteroid receptor in neuronal membranes associated with rapid suppression of sexual behavior. In “Neurosteroids and Brain Function,” C.E. Costa and S.M. Paul (Eds.), FIDIA Sympos Series, 8, 125–132, 1991.
54. Gale, K., Zhong, P., Miller, L.P. and Murray, T.F.: Amino acid neurotransmitter interactions in 'area tempestas': an epileptogenic trigger zone in the deep prepiriform cortex, Epilepsy Research, Suppl. 8, 229– 234, 1992.
55. Murray, T.F., Franklin, P.H., Zhang, G. and Tripp, E.: A1 adenosine receptors express seizure suppressant activity in the rat prepiriform cortex, Epilepsy Research, Suppl. 8, 255–261, 1992.
11 Thomas F. Murray
56. Franklin, P.H. and Murray, T.F.: High affinity [3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated NMDA receptor-cation channel. Molecular Pharmacol., 41, 134–146, 1992.
57. Steketee, J.D., Striplin, C.D., Murray, T.F. and Kalivas, P.W.: Pertussis toxin in the A10 region increases dopamine synthesis and metabolism. J. Neurochem., 58, 811–816, 1992.
58. Orchinik, M., Murray, T.F., Franklin, P.H. and Moore, F.L.: Guanyl nucleotides modulate binding to steroid receptors in neuronal membranes. Proc. Natl. Acad. Sci., USA, 89, 3830–3834, 1992.
59. Roth, J.E., Zhang, G., Murray, T.F. and Franklin, P.H.: Dextrorotatory opioids and phencyclidine exert anticonvulsant action in prepiriform cortex. Eur. J. Pharmacol., 215, 293–296, 1992.
60. Murray, T.F., Roth, J.E. and Franklin, P.H.: High affinity [3H]dextrorphan recognition site of the NMDA- operated cation channel mediates the anticonvulsant actions of dextrorotatory opioids and phencyclidine. In “Multiple Sigma and PCP Receptor Ligands. Mechanisms for Neuromodulation and Neuroprotection.” Edited by J.-M. Kamenka and E.F. Domino, NPP Books, Ann Arbor, MI, 695–714, 1992.
61. Koos, B.J., Murray, T.F. and Doany, W.: Anemia up-regulates pontine A1 adenosine receptors in fetal sheep. Brain Research, 579, 291–295, 1992.
62. Story, S.C., Murray, T.F., DeLander, G.E. and Aldrich, J.V.: Synthesis and opioid activity of 2-substituted dynorphin A-(1-13) amide analogues. Int. J. Peptide Protein Res., 40, 89–96, 1992.
63. Heekyung, C., DeLander, G.E., Murray, T.F., Anderson, S. and Aldrich, J.V.: Synthesis and opioid activity of dynorphin A-(1-13) analogues substituted at positions 2 and 4,“ in Peptides: Chemistry and Biology: Proceedings of the 12th American Peptide Symposium, J.A. Smith and J.E. Rivier, Eds., ESCOM Science Publishers: Leiden, The Netherlands, 1992; pp. 134–135.
64. Snyder, K.R., Story, S.C., Heidt, M.E., Murray, T.F., DeLander, G.E. and Aldrich, J.V.: Effect of modification of the basic residues of dynorphin A-(1-13) amide on kappa opioid receptor selectivity and opioid activity. Journal of Medicinal Chemistry, 35, 4330–4333, 1992.
65. Choi, H., Murray, T.F., DeLander, G.E., Caldwell, V. and Aldrich, J.V.: N-terminal alkylated derivatives of [D-pro10]dynorphin A(1-11) are highly selective for kappa opioid receptors. J. Med. Chem, 35, 4638– 4639, 1992.
66. Zhang, G., Franklin, P.H. and Murray, T.F.: Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J. Pharmacol. Exp. Ther., 264, 1415–1424, 1993.
67. Snyder, K.R., Murray, T.F., DeLander, G.E., and Aldrich, J.V.: Synthesis and opioid activity of dynorphin A-(1-13)NH2 analogues containing cis- and trans-4-aminocyclohexanecarboxylic acid. J. Med. Chem., 36, 1100–1103, 1993.
68. Murray, T.F., Zhang, G. and Franklin, P.H.: Manipulation of endogenous adenosine affects seizure susceptibility. Drug Develop. Res., 28, 410–415, 1993.
69. Roth, J.E., Franklin, P.H. and Murray, T.F.: The F ligand 1,3-di(2-tolyl)guanidine is anticonvulsant in the rat prepiriform cortex. Eur. J. Pharmacol., 236, 327–331, 1993.
70. Musser, B., Morgan, M.E., Leid, M., Murray, T.F., Linden, J. and Vestal, R.E.: Species comparison of adenosine and -adrenoceptors in mammalian atrial and ventricular myocardium. Eur. J. Pharmacol.-Mol. Pharmacol. Sect., 246, 105–112, 1993.
12 Thomas F. Murray
71. Murray, T.F. and Siebenaller, J.F.: Differential susceptibility of guanine nucleotide-binding proteins to pertussis toxin catalyzed ADP-ribosylation in brain membranes of two congeneric marine fishes. Biological Bulletin. 185, 346–354, 1993.
72. Murray, T.F.: Basic pharmacology of ketamine. In: The Pharmacologic Basis of Anesthesiology – Basic Science and Clinical Application. Churchill Livingstone, NY, pp. 337–355, 1994.
73. Siebenaller, J.F. and Murray, T.F.: The effects of hydrostatic pressure on the low-Km GTPase in brain membranes from two congeneric marine fishes. J. of Comparative Physiol. B., 163, 626-632, 1994.
74. Orchinik, M. and Murray, T.F.: Steroid hormone binding to membrane receptors. In: Methods in Neuroscience: Neurobiology of Steroids. Eds. E.R. deKloet and W. Sutanto, Academic Press, Orlando, FL, 22, 96–115, 1994.
75. Zhang, G., Franklin, P.F. and Murray, T.F.: Activation of adenosine A1 receptors underlies anticonvulsant effect of CGS21680. Eur. J. Pharmacol., 255, 239–243, 1994.
76. Orchinik, M., Murray, T.F. and Moore, F.L.: Steroid modulation of GABAA receptors in an amphibian brain. Brain Res., 646, 258–266, 1994.
77. Maeda, D.Y., Murray, T.F., Roth, J.E. and Aldrich, J.V.: Synthesis of enkephalin-based affinity labels for delta opioid receptors. Regulatory Peptides 54, 171-172, 1994.
78. Siebenaller, J.F. and Murray, T.F.: The effects of hydrostatic pressure on pertussis toxin-catalyzed ribosylation of guanine nucleotide binding proteins from two congeneric marine fishes. Comparative Biochemistry and Physiology, 108B, 423–430, 1994.
79. Siebenaller, J.F. and Murray, T.F.: Membrane preparation and receptor assays – adenosine. In: Biochemistry and Molecular Biology of Fishes. Hochachka and Mommsen Eds. Elsevier Science, Amsterdam, Vol. 3, pp. 477–486, 1994.
80. Arttamangkul, S., Murray, T. F., DeLander, G.E, and Aldrich, J.V.: Synthesis and opioid activity of conformationally constrained dynorphin A analogues: Part I. Conformational constraint in the “message sequence.” J. Med. Chem., 38, 2410-2417, 1995.
81. Siebenaller, J.F. and Murray, T.F.: The effects of pressure on G-protein coupled signal transduction. In: Biochemistry and Molecular Biology of Fishes. P.W. Hochachka and T.P. Mommsen, Eds. Elsevier Science, Amsterdam. Vol. 5, pp. 147-174. 1995.
82. Wise, M.L., Soderstrom, K., Murray, T.F., and Gerwick, W.H.: Synthesis and cannabinoid receptor binding activity of conjugated triene anandimide, a novel eicosanoid. Experentia, 52, 88-92, 1996.
83. Roth, J.E., Murray, T.F. and Franklin, P.H.: Regional distribution and characterization of [3H]dextrorphan binding sites in rat brain determined by quantitative autoradiography. J. Pharmacol. Exp. Ther., 277, 1823- 1836, 1996.
84. Hettinger-Smith, B.D., Leid, M. and Murray, T.F.: Chronic exposure to adenosine receptor agonists and antagonists reciprocally regulates the A1 adenosine receptor-adenylyl cyclase system in cerebellar granule cells. J. Neurochem., 67, 1921-1930, 1996.
85. Roth, J.E., Franklin, P.H., Murray, T.F. and Leid, M.: High level expression of the NMDAR1 glutamate receptor subunit in electroporated COS cells. J. Neurochem., 67, 1500-1510, 1996.
86. Berman, F.W. and Murray, T.F.: Characterization of glutamate toxicity in cultured rat cerebellar granule neurons at reduced temperature. J. of Biochem. Toxicol., 11, 111-119, 1996.
13 Thomas F. Murray
87. Berman, F.W. and Murray, T.F.: Characterization of [3H]MK-801 binding to NMDA receptors expressed in rat cerebellar granule neurons in culture. J. of Biochem. Toxicol., 11, 217-226, 1996.
88. Arttamangkul, S., Ishmael, J.E., Murray, T.F., Grandy, D.K., DeLander, G.E., Kieffer, B.L. and Aldrich, J.V.: Synthesis and opioid activity of conformationally constrained dynorphin A analogues: Part II. Conformational constraint in the "address sequence." J. Med. Chem., 40, 1211-1218, 1997.
89. Berman, F. and Murray, T.F.: Domoic acid neurotoxicity in cultured cerebellar granule neurons is predominantly mediated by NMDA receptors that are activated as a consequence of excitatory amino acid release. J. Neurochem., 69, 693-703, 1997.
90. Zhang, G., Murray, T.F. and Grandy, D.K.: Orphanin FQ, the endogenous agonist for the opioid-like orphan receptor LC132, has an inhibitory effect on guinea-pig ileum and mouse vas deferens. Brain Res., 772, 102-106, 1997.
91. Soderstrom, K., Choi, H., Aldrich, J.V. and Murray, T.F.: N-alkylated derivatives of [D-Pro10] dynorphin A (1-11) are high affinity partial agonists at the cloned rat 6-opioid receptor. Europ. J. Pharmacol., 338, 191-197, 1997.
92. Choi, H., Murray, T.F., DeLander, G.E., Schmidt, W.K. and Aldrich, J.V.: Synthesis and opioid activity of [D-Pro10] Dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J. Med. Chem, 40, 2733- 2739, 1997.
93. Knutsen, L.J.S. and Murray, T.F.: Adenosine and ATP in epilepsy. In: Purinergic Approaches in Experimental Therapeutics, K.A. Jackbson and M.F. Jarvis, Eds. Wiley-Liss, Inc., New York, pp. 423-447, 1997.
94. Gerwick, W.H., Wise, M.L., Soderstrom, K. and Murray, T.F. Biosynthesis and cannabinoid receptor affinity of the novel eicosanoid, conjugated triene anandamide. Adv. Exp. Med. Biol. 407:329-334, 1997.
95. Koos, B.J., Kruger, L. and Murray, T.F. Source of extracellular brain adenosine during hypoxia in fetal sheep. Brain Res. 778, 439-442, 1997.
96. Soderstrom, K., Murray, T.F., Yoo, H.D., Ketchum, S., Milligan, K., Gerwick, W., Ortega, M.J. and Salva, J. Discovery of novel cannabinoid receptor ligands from diverse marine organisms. Adv. Exp. Med. Biol., 433, 73-77, 1997.
97. Hettinger, B.D., Leid, M. and Murray, T.F. Cyclopentyladenosine-induced homologous downregulation of A1 adenosine receptors (A1AR) in intact neurons is accompanied by receptor sequestration but not a reduction in A1AR mRNA expression or G-protein " subunit content. J. Neurochem., 71, 221-230, 1998.
98. Evans, S.J., Moore, F.L. and Murray, T.F. Solubilization and pharmacological characterization of a glucocorticoid membrane receptor from an amphibian brain. J. of Steroid Biochem. and Mol. Biol. 67, 1-8, 1998.
99. Bouvier, C., Avram, D., Peterson, U.A., Hettinger, B., Soderstrom, K., Murray, T.F. and Leid, M. Catecholaminergic CATH.a cells express predominantly delta opioid receptors. Europ. J. Pharmacol., 348, 85-93, 1998.
100. Ishmael, J.E., Franklin, P.H. and Murray, T.F. Dextrorotatory opioids induce stereotyped behavior in Sprague-Dawley and Dark Agouti rats. Psychopharmacology, 140, 206-216, 1998.
101. Berman, F.W., Gerwick, W.H. and Murray, T.F. Antillatoxin and kalkitoxin, ichthyotoxins from the tropical cyanobacterium Lyngbya majuscula, induce distinct temporal patterns of NMDA receptor- mediated neurotoxicity. Toxicon, 37, 1645-1648, 1999.
14 Thomas F. Murray
102. Berman, F.W. and Murray, T.F. Brevetoxins cause acute excitotoxicity in primary cultures of rat cerebellar granule neurons. J. Pharmacol. Exp. Ther., 290, 439-444, 1999.
103. Wan, Q, Murray, T.F. and Aldrich, J.V. A novel acetylated analogue of Dynorphin A-(1-11) amide as a 6 opioid receptor antagonist. J. Med. Chem., 42, 3011-3013, 1999.
104. Siebenaller, J.F. and Murray, T.F. Hydrostatic pressure alters the time course of GTP[S]binding to G proteins in brain membranes from two congeneric marine fishes. Biological Bulletin, 197, 388-394, 1999.
105. Berman, F.W. and Murray, T.F. Brevetoxin-induced autocrine excitotoxicity is associated with manifold routes of Ca2+ influx. J. Neurochem., 74, 1443-1451, 2000.
106. Evans, S.J., Murray, T.F. and Moore, F.L. Partial purification and biochemical characterization of a membrane glucocorticoid receptor from an amphibian brain. J. Steroid Biochem. 72, 209-221, 2000.
107. Soderstrom, K., Leid, M., Moore, F.L. and Murray, T.F. Behavioral, pharmacological and molecular characterization of an amphibian cannabinoid receptor. J. Neurochem., 75, 413-423, 2000.
108. Maeda, D.Y., Ishmael, J.E., Murray, T.F. and Aldrich, J.V. Synthesis and evaluation of N,N-dialkyl enkephalin-based affinity labels for -opioid receptors. J. Med. Chem., 43, 3941-3948, 2000.
109. Kumar, V., Murray, T.F. and Aldrich, J.V. Extended TIP (P) analogs as precursors for labeled -opioid receptor ligands. J. Med. Chem., 43, 5050-5054, 2000.
110. Maeda, D.Y., Berman, F., Murray, T.F. and Aldrich, J.V. Synthesis and evaluation of Isothiocyanate- containing derivatives of the -opioid receptor antagonist Tyr-Tic-PhrPhe (TIPP) as potential labels for - opioid receptors. J. Med. Chem., 43, 5044-5049, 2000.
111. Wu, M., Okino, T., Nogle, L.M., Marquez, B.L., Williamson, R.T., Sitachitta, N., Berman, F.W., Murray, T.F., McGough, K., Jacobs, R., Colsen, K., Asano, T., Yokokawa, F., Shioire, T., and Gerwick, W.H. Structure, synthesis, and biological properties of kalkitoxin, a novel neurotoxin from the marine cyanobacterium Lyngbya majuscula. J. Am. Chem. Soc., 122, 12041-12042, 2000.
112. Aldrich, J.V., Zheng, Q.L. and Murray, T.F. Dynorphin A analogs containing a conformationally constrained phenylalanine derivative in position 4: reversal of preferred stereochemistry for opioid receptor affinity and discrimination of kappa vs. delta receptors. Chirality, 13 125-129, 2001.
113. Li, W.I., Berman, F.W., Okino, T., Yokokawa, F., Shioire, T., Gerwick, W.H. and Murray, T.F. Antillatoxin is a novel marine cyanobacterial toxin that potently activates voltage-gated sodium channels. Proc. Natl. Acad. Sci. USA, 98, 7599-7604, 2001.
114. Berman, F.W., LePage, K.T. and Murray, T.F. Domoic acid neurotoxicity in cultured cerebellar granule neurons is controlled preferentially by the NMDA receptor Ca2+ influx pathway. Brain Res., 924, 20-29, 2002.
115. Garczynski, S.F., Brown, M.R., Shen, P., Murray, T.F., and Crim, J.W. Characterization of a functional neuropeptide F receptor from Drosophila melanogaster. Peptides. 23:773-80, 2002.
116. Vandenplas, M.L., Carlson, R.W., Jeyaretnam, B.S., McNeill, B., Barton, M.H., Norton, N., Murray, T.F. and Moore, J.N. Rhizobium sin-1 lipopolysaccharide (LPS) prevents enteric LPS-induced cytokine production. J. Biol Chem. 227, 41811-6, 2002.
117. Kumar, V., Murray, T.F. and Aldrich, J.V. Solid phase synthesis and evaluation of Tyr-Tic-Phe-Phe(p- NHCOCH(2)Br) ([Phe(p-bromoacetamide)(4)]TIPP), a potent affinity label for delta opioid receptors. J Med Chem., 45, 3820-3, 2002.
15 Thomas F. Murray
118. Wolfert, M.A., Murray, T.F., Boons, G.J. and Moore, J.N. The origin of the synergistic effect of muramyl dipeptide with endotoxin and peptidoglycan. J Biol Chem. 227, 39179-86, 2002.
119. Bennett, M.A., Murray, T.F. and Aldrich, J.V. Identification of arodyn, a novel acetylated dynorphin A-(1- 11) analogue, as a kappa opioid receptor antagonist. J Med Chem. Dec. 19;45(26):5617-5619, 2002.
120. Choi, H., Murray, T.F., Aldrich, J.V. Dermorphin-based potential affinity labels for mu-opioid receptors. J Pept Res. 61:45-5, 2003.
121. LePage, K.T., Baden, D.G. and Murray, T.F. Brevetoxin derivatives act as partial agonists at neurotoxin site 5 on the voltage-gated Na(+) channel. Brain Res. 959:120-127, 2003.
122. Choi, H., Murray, T.F., Aldrich, J.V. Synthesis and evaluation of potential affinity labels derived from endomorphin-2. J Pept Res 61:58-62, 2003.
123. Dravid, S. and Murray, T.F. Fluorescent detection of Ca2+-permeable AMPA/kainite receptor activation in murine neocortical neurons. Neurosci Letts 351:145-148, 2003.
124. Heekyung, C., Murray, T.F. and Aldrich, J.V. Synthesis and evaluation of derivatives of leucine enkephalin as potential affinity labels for δ opioid receptors. Biopolymers (Peptide Science) 71:552-557, 2003.
125. Vig, B.S., Murray, T.F., and Aldrich, J.V. Synthesis of novel basic head-to-side-chain cyclic dynorphin A analogs:strategies and side reactions. Biopolymers. 71(6):620-37, 2003
126. Dravid, S. and Murray, T.F. Spontaneous synchronized calcium oscillations in neocortical neurons in the presence of physiological [Mg2+]: involvement of AMPA/kainate and metabotropic glutamate receptors. Brain Res. 1006:8-17, 2004.
127. Li, W.I., Marquez, B.L., Okino, T., Yokokawa, F., Shioiri, T., Gerwick, W.H. and Murray, T.F. Characterization of the preferred stereochemistry for the neuropharmacologic actions of antillatoxin. J. of Natural Products. 67:559-568, 2004.
128. Miller, C.C., Murray, T.F., Freeman, K.G., and Edwards, G.L. Cannabinoid agonist, CP 55,940, facilitates intake of palatable foods when injected into the hindbrain. Phys & Behav. 80:611-616, 2004.
129. Aldrich, J.V., Choi, H., and Murray, T.F. An affinity label for delta-opioid receptors derived from [D- Ala2]deltorphin I. J Pept Res. 63:108-15, 2004.
130. Dravid, S.M., Baden, D.G. and Murray, T.F. Brevetoxin activation of voltage-gated sodium channels regulates Ca dynamics and ERK1/2 phosphorylation in murine neocortical neurons. J. Neurochem. 89:739- 49, 2004.
131. Dravid, S.M., Baden, D.G. and Murray, T.F. Brevetoxin augments NMDA receptor signaling in murine cortical neurons. Brain Res. 1031: 30-38, 2005.
132. LePage, K.T., Ishmael, J.E., Low, C.M. Traynelis, S.F. and Murray, T.F. Differential binding properties of [3H]dextrorphan and [3H]MK-801 in heterologously expressed NMDA receptors. Neuropharmacology. 49:1-16, 2005.
133. Bennett, M.A., Murray, T.F. and Aldrich, J.V. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist*dagger. J Pept Res. 65:322-32, 2005.
134. Johnson, V.J., Tsunoda, M., Murray, T.F. and Sharma, R.P. Decreased membrane fluidity and hyperpolarization in aluminum-treated PC-12 cells correlates with increased production of cellular oxidants. Environmental Toxicology and Pharmacology. 19:221-230, 2005.
16 Thomas F. Murray
135. LePage K.T., Goeger, D., Yokokawa, F., Shioiri T., Gerwick,W.H. and Murray, T.F. The neurotoxic lipopetide kalkitoxin interacts with voltage-sensitive sodium channels in cerebellar granule neurons. Toxicol Letters. 158:133-139, 2005.
136. Patkas, K.A., Yan, X., Murray, T.F. and Aldrich, J.V. [Nα-Benzyl Tyr; cyclo (D-Asp5, Dap8)]-dynorphin A – (1-11) NH2 cyclized in the “address” domain is a novel -opioid receptor antagonist. J. Med. Chem. 48: 4500-4503, 2005.
137. LePage KT, Dickey RW, Gerwick WH, Jester EL and Murray TF. On the use of neuro-2a neuroblastoma cells versus intact neurons in primary culture for neurotoxicity studies.Crit Rev Neurobiol 17:27-50, 2005.
138. Sabry, O.M., Andrews, S., McPhail, K.L., Goeger, D.E., Yokochi, A., LePage, K.T., Murray, T.F. and Gerwick, W.H. Neurotoxic meroditerpenoids from the tropical marine brown alga Stypopodium flabelliforme. J. Nat. Prod. 68: 1022-1030, 2005.
139. Brandon, C.I., Vandenplas, M., Dookwah, H., Linden, J. and Murray, T.F. Cloning and pharmacological characterization of the equine adenosine A2A receptor: a potential therapeutic target for the treatment of equine. J. Vet Pharmacol. Therap. 29: 243-253, 2006.
140. Brandon, C.I., Vandenplas, M., Dookwah, H. and Murray, T.F. Cloning and pharmacological characterization of the equine adenosine A3 receptor. J. Vet Pharmacol. Therap. 29: 255-263, 2006.
141. Yan, X., Koos, B.J., Kruger, L., Linden, J., and Murray, T.F. Characterization of [125I]ZM 241385 binding to adenosine A2A receptors in the pineal of sheep brain. Brain Res. 1096: 30-39, 2006.
142. Yan X, Benson JM, Gomez AP, Baden DG, Murray TF. Brevetoxin-induced neural insult in the retrosplenial cortex of mouse brain. Inhal Toxicol. 18:1109-16, 2006.
143. Sun, W-C., Moore, J.N., Hurley, D.J., Vadenplas, M.L. and Murray, T.F. Adenosine A2A receptor stimulation inhibits LPS-induced production of ROS by equine neutrophils in a cAMP-dependent, PKA- independent manner. Am. J. Vet. Res. 68: 649-56, 2007.
144. Dravid S.M., Erreger K., Yuan H., Nicholson K., Le P., Lyuboslavsky P., Almonte A., Murray E., Mosely C., Barber J., French A., Balster R., Murray T.F., Traynelis S.F. Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol. 581: 107-28, 2007.
145. LePage K.T., Rainier J.D., Johnson H.W.B., Baden D.G. and Murray T.F. Gambierol Acts as a Functional antagonist of neurotoxin site 5 on voltage-gated sodium channels in cerebellar granule neurons. J Pharmacol. Exp. Ther. 323, 174-179, 2007.
146. Sun, W.S., Moore, J.N., Hurley, D.J., Vandenplas, M.L., Linden, J., Cao, Z. and Murray, T.F.Adenosine A2A receptor agonists inhibit lipopolysaccharide-induced production of tumor necrosis factor-alpha by equine monocytes. Veterinary Immunol. and Immunopath. 121, 91-100, 2008.
147. Sun W.C., Moore J.N., Hurley D.J., Vandenplas M.L., Linden J.M., Murray T.F. Pharmacologic characterization of novel adenosine A2A receptor agonists in equine neutrophils. Am J Vet Res. 68, 981- 987, 2007.
148. Cao, Z., George, J., Baden, D.G. and Murray, T.F. Brevetoxin-induced phosphorylation of Pyk2 and Src in murine neocortical neurons involves distinct signaling pathways. Brain Res, 1184, 17-27, 2007.
149. Figueiredo, M.D., Moore, J.N., Vandenplas,M.L., Sun, W. and Murray, T.F. Inhibition of endotoxin responses in equine whole blood and monocytes by E5564. Am J Vet Res. 69, 796-803, 2008.
17 Thomas F. Murray
150. Aldrich,J.V., Kumar, V., Dattachowdhury, B., Peck, A.M., Wang, X. and Murray, T.F. Solid Phase Synthesis and Application of Labeled Peptide Derivatives: Probes of Receptor-Opioid Peptide Interactions. International Journal of Peptide Research and Therapeutics. 14, 315-321, 2008.
151. Cao, Z., George, J., Gerwick W.H., Baden, D.G., Rainier, J.D. and Murray, T.F. Influence of lipid soluble gating modifier toxins on sodium influx in neocortical neurons. J Pharmacol. Exp. Ther. 326, 604-613, 2008.
152. Aldrich, J.V., Kumar, V., Murray, T.F., Guang, W. and Wang J.B. Dual Labeled Peptides as Tools to Study Receptors: Nanomolar Affinity Derivatives of TIPP (Tyr-Tic-Phe-Phe) Containing an Affinity Label and Biotin as Probes of delta Opioid Receptors. Bioconjug Chem. 20, 201-204, 2009.
153. George J, Dravid SM, Prakash A, Xie J, Peterson J, Jabba SV, Baden DG and Murray TF. Sodium channel activation augments NMDA receptor function and promotes neurite outgrowth in immature cerebrocortical neurons. J Neurosci. 29, 3288-3301, 2009.
154. Sinha, B, Cao, Z, Murray, TF and Aldrich, JV. Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors. J Med Chem. 52, 7372-75, 2009.
155. Pereira A., Cao, Z, Murray TF and Gerwick WH. Hoiamide A, a cyclic peptide of unusual architecture from Papua New Guinea cyanobacteria, is a sodium channel activator. Chemistry and Biology. 16, 893- 906, 2009.
156. Suyama, TL, Cao, Z, Murray, TF and Gerwick, WH. Ichthyotoxic brominated diphenyl ethers from a mixed assemblage of a red alga and cyanobacterium: structure clarification and biological properties. Toxicon, 55, 204-210, 2009.
156. Jabba, SV, Prakash A, Dravid, SM, Gerwick WH and Murray TF. Antillatoxin, a novel lipopeptide, enhances neurite outgrowth in immature cerebrocortical neurons through activation of voltage- gated sodium channels. J Pharmacol. Exp. Ther. 332, 698-709, 2010.
157. Fang W-J, Cui Y, Murray TF and Aldrich JV. Design, synthesis, and pharmacological activities of dynorphin A analogs cyclized by ring-closing metathesis. J Med Chem, 52, 5619-5625, 2009.
158. Patkar, K, Murray, TF and Aldrich, JV. The effects of C-terminal modifications on the opioid activity of [N-BenzylTyr1]dynorphin A-(1-11) analogs. J Med Chem, 52, 6814-6822, 2009.
159. Soria-Mercado IE, Pereira A, Cao Z, Murray TF and Gerwick WH. Alotamide A, A novel neuropharmacological agent from the marine cyanobacterium Lyngbya bouillonii. Org Lett. 11, 4704- 4707, 2009.
160. Cao, Z., Lepage, K.T., Frederick, M.O., Nicolaou, K.C. and Murray, T.F. Involvement of caspase activation in azaspiracid-induced neurotoxicity in neocortical neurons. Toxicological Sciences, in press, 2010.
Abstracts:
1. Murray, T.F., and Horita A.: Effects of phencyclidine on operant behavior in rats. Pharmacologist 19, 228, 1977.
2. Murray, T.F., and Horita, A.: Dose response effects of phencyclidine on stereotyped behavior in rats. Society for Neuroscience Absts 4, 498, 1978.
18 Thomas F. Murray
3. Murray, T.F., and Horita, A.: Phencyclidine: Correlation of brain levels with behavioral effects and absence of a dispositional component to the observed tolerance. Fed. Proc. 38, 438, 1979.
4. Murray, T.F., Cheney, D.L., and Costa, E.: The effect of phencyclidine on the turnover rate of acetylcholine in various regions of rat brain. Pharmacologist 22, 164, 1980.
5. Murray, T.F., and Cheney, D.L.: Levonantradol-induced inhibition of acetylcholine turnover in rat hippocampus and striatum. Fed. Proc. 40, 279, 1981.
6. Murray, T.F., Cheney, D.L., and Costa, E.: Modification of cholinergic dynamics in rat brain by intraventricular administration of adenosine analogs, Society for Neuroscience Absts. 7, 495, 1981.
7. Murray, T.F., Cheney, D.L., and Costa, E.: Regulation of hippocampal and cortical acetylcholine turnover in rat brain by adenosine analogs. “International Symposium on Adenosine,” Charlottesville, VA, June 7– 11, 1982, p. 167.
8. Murray, T.F., Leid, M.E., Zaro, B.J., and Klavano, P.: Stereospecific displacement of 3H-phencyclidine binding by dextrorphan and comparison of behavioral effects in dogs. Society for Neuroscience Absts. 8, 388, 1982.
9. Zobrist, R.H., Komiskey, H.L., and Murray, T.F.: Influence of age on β-carboline binding in hippocampal subfields. Society for Neuroscience Absts. 8, 573, 1982.
10. Murray, T.F., Cheney, D.L., and Costa, E.: A comparison of phenycyclindine with other psychoactive drugs on cholinergic dynamics in the rat brain. Substance and Alcohol Actions/Misuse. 4, 476, 1983.
11. Murray, T.F., and Leid, M.E.: Phencyclidine displaceable binding of [3H]dextrorphan in rat brain membranes. Society for Neuroscience Absts. 9, 328, 1983.
12. Szot, P., and Murray, T.F.: Comparison of the effects of ethanol and 2-chloroadenosine on the high affinity choline uptake in rat brain using improved methodology. Society for Neuroscience Absts. 9, 1237, 1983.
13. Szot, P., and Murray, T.F.: Adenosine receptor agonists elevate seizure threshold in rats. Society for Neuroscience Absts. 10, 2, 1984.
14. Sanders, R.C., Szot, P., and Murray, T.F.: Theophylline-induced up-regulation of cerebellar adenosine A1 receptors in neonatal rats. Society for Neuroscience Absts. 10, 672, 1984.
15. Murray, T.F., Mpitsos, G.J., Siebenaller, J.F., and Barker, D.L.: Demonstration of stereoselective L- [3H]QNB binding sites in nervous tissue of Aplysia californica and Pleurobranchaea californica. Society for Neuroscience Absts. 11, 481, 1985.
16. Barker, D.L., Murray, T.F., Mpitsos, G.J., and Siebenaller, J.F.: Characterization of muscarinic receptors in crustacean nervous tissue by [3H]QNB binding. Society for Neuroscience Absts. 11, 325, 1985.
17. Murray, T.F., Siebenaller, J.F.: Phylogenetic distribution of A1 adenosine receptors in nervous tissue. Proc. West. Pharmacol. Soc. 29, 49, 1986.
18. Murray, T.F., and Mpitsos, G.J.: Characterization of high-affinity binding sites for [125I]3-quinuclidinyl 4-iodobenzilate in nervous tissue of the gastropod mollusc Pleurobranchaea californica. Society for Neuroscience Absts. 12, 240, 1986.
19. Barker, D.L., Murray, T.F., Siebenaller, J.F., and Mpitsos, G.J.: Computer analyzed 2D gels reveal effects of muscarinic ligands on synthesis of specific proteins in the nervous system of Pleurobranchaea californica. Society for Neuroscience Absts. 12, 400, 1986.
19 Thomas F. Murray
20. Szot, P, Sanders, R.C., and Murray, T.F.: Theophylline-induced upregulation of A1 adenosine receptors associated with reduced sensitivity to chemoconvulsants in rats. Society for Neuroscience Absts. 12, 615, 1986.
21. Mpitsos, G.J., Murray, T.F., Creech, H.C., and Barker, D.L.: Muscarinic antagonist scopolamine enhances one-trial Pavlovian conditioning in the gastropod mollusc Pleurobranchaea. Society for Neuroscience Absts. 12, 710, 1986.
22. Devaud, L. and Murray, T.F.: Proconvulsant effects of Type I pyrethroids: Involvement of the peripheral- type benzodiazepine receptor. Pharmacologist, 29, 123, 1987.
23. Murray, T.F. and Siebenaller, J.F.: Comparison of the binding properties of A1 adenosine receptors in brain membranes of two congeneric marine fishes. Pharmacologist, 29, 145, 1987.
24. Leid, M., Franklin, P.H. and Murray, T.F.: Characterization of A1 adenosine receptors in porcine atrial membranes. Pharmacologist, 29, 145, 1987.
25. Blair, T.A. and Murray, T.F.: Development of physiological responsiveness to adenosine analogs in embryonic chick heart. Society for Neuroscience Absts. 13, 739, 1987.
26. Devaud, L. and Murray, T.F.: Interactions of pyrethroid insecticides with the peripheral-type benzodiazepine receptor. Society for Neuroscience Absts. 13, 1230, 1987.
27. Eshleman, A.J. and Murray, T.F.: Characterization of specific [3H]PK11195 binding sites in rainbow trout brain membranes. Society for Neuroscience Absts. 13, 932, 1987.
28. Franklin, P.H., Tripp, E.D., Fabrazzo, M., Gale, K and Murray, T.F.: Adenosine receptor mediated modulation of seizure activity originating in the prepiriform cortex. Society for Neuroscience Absts. 13, 1631, 1987.
29. Leid, M., Franklin, P.H. and Murray, T.F.: Characterization of A1 adenosine receptors in porcine atrial membranes. Society for Neuroscience Absts. 13, 1487, 1987.
30. Sanders, R.C., Szot, P. and Murray, T.F.: Temporal relationship between theophylline- inducedupregulation of central A1 adenosine receptors and alteration of seizure susceptibility. Society for Neuroscience Absts. 13, 723, 1987.
31. Leid, M., Franklin, P.H. and Murray, T.F.: Characterization of cardiac A1 adenosine receptors with the antagonist radioligand 8-cyclopentyl-1,3[3H]-dipropylxanthine. Proc. West. Pharmacol. Soc. 31, 103, 1988.
32. Franklin, P.H., Zhang, G., Tripp, E.D. and Murray T.F.: A1 adenosine receptor activation blocks seizures induced by bicuculline methiodide in the rat prepiriform cortex. Society for Neuroscience Absts. 14, 7, 1988.
33. Eshleman, A.J. and Murray, T.F.: Opposite modulation of [35S]t-butylbicyclophosphorothionate binding by deltamethrin and Ro5-4864 in trout brain membranes. Society for Neuroscience Absts. 14, 168, 1988.
34. Devaud, L.L. and Murray, T.F.: Inhibitory modulation of GABA-gated chloride influx by Ro5-4864 and deltamethrin in rat brain synaptoneurosomes. Society for Neuroscience Absts. 14, 450, 1988.
35. Blair, T.A. and Murray, T.F.: Development of A1 adenosine receptors and responsiveness of adenylate cyclase to inhibition by cyclopentyladenosine in embryonic chick heart. Society for Neuroscience Absts. 14, 972, 1988.
20 Thomas F. Murray
36. Leid, M. and Murray, T.F.: Agonist radioligand interactions with the solubilized porcine atrial adenosine receptor. Society for Neuroscience Absts. 14, 972, 1988.
37. Leid, M. and Murray, T.F.: Characterization of cardiac A1 adenosine receptor-G protein interactions in detergent solution. FASEB J. 3, A280, 1989.
38. Zhang, G., Franklin, P.H. and Murray, T.F.: Activation of adenosine receptors suppresses behavioral seizures induced by kainic acid in the rat prepiriform cortex. Proc. West. Pharmacol. Soc. 32, 149, 1989.
39. Leid, M., Murray, T.F., Franklin, P.H. and Siebenaller, J.F.: A1 adenosine receptor regulation of adenylyl cyclase activity in brain membranes of a deep-living teleost fish. Soc. for Neuroscience Absts. 15, 233, 1989.
40. Zhang, G., Franklin, P.H. and Murray, T.F.: Modulation of kainic acid-induced behavioral seizures in rat prepiriform cortex by adenosine receptor activation and antagonism. Soc. for Neuroscience Absts. 15, 339, 1989.
41. Blair, T.A. and Murray, T.F.: Cyclopentyladenosine-induced downregulation of A1 adenosine receptors in embryonic chick heart. Soc. for Neuroscience Absts. 15, 974, 1989.
42. Eshleman, A.J. and Murray, T.F.: Pyrethroid insecticides and veratridine increase basal chloride uptake into rainbow trout synaptoneurosomes. Soc. for Neuroscience Absts. 15, 1153, 1989.
43. Franklin, P.H. and Murray, T.F.: High affinity [3H]dextrorphan recognition sites in rat brain are associated with the NMDA-operated cation channel. Soc. for Neuroscience Absts. 16, 88, 1990.
44. Orchinik, M., Murray, T.F. and Moore, F.L.: Novel steroid-binding site on synaptic membranes may mediate stress-induced inhibition of sexual behaviors. Soc. for Neuroscience Absts. 16, 765, 1990.
45. Murray, T.F. and Jacobsen, T.F.: Modulation of [35S]-t-butylbicyclophosphorothionate binding to intact cerebellar granule cells by the type I pyrethroid deltamethrin. Soc. for Neuroscience Absts. 16, 805, 1990.
46. Zhang, G., Franklin, P.H., Murray, T.F.: Influence of adenosine transport and adenosine deaminase inhibitors on bicuculline methiodide-induced seizures in rat prepiriform cortex. Soc. for Neuroscience Absts. 16, 948, 1990.
47. Golden, R.L. and Murray, T.F.: Modulation of [35S]t-butylbicyclophosphorothionate kinetics by deltamethrin in rainbow trout brain membranes. Soc. for Neuroscience Absts. 16, 1117, 1990.
48. Zhang, G. and Murray, T.F.: Manipulation of endogenous adenosine levels in rat prepiriform cortex modulates seizure susceptibility. The Pharmacologist, 33, 196, 1991.
49. Ishmael-Roth, J.E., Franklin, P.H. and Murray, T.F.: Dextrorotatory opioids and phencyclidine exert anticonvulsant action in rat prepiriform cortex. Soc. for Neurosci. Absts., 17, 588, 1991.
50. Orchinik, M., Murray, T.F. and Moore, F.L.: Membrane-bound corticosteroid receptor is coupled to a G- protein. Soc. for Neurosci. Absts., 17, 1408, 1991.
51. Zhang, G. and Murray, T.F.: Adenosine kinase and adenosine deaminase inhibition in rat prepiriform cortex confers protection against bicuculline methiodide-induced seizures. Soc. for Neuroscience Absts., 17, 1492, 1991.
52. Murray, T.F. and Caldwell, V.J.: Glutamate sensitive binding of [125I]MK801 to intact cerebellar granule cells. Soc. for Neuroscience Absts., 18, 1156, 1992.
21 Thomas F. Murray
53. Franklin, P.H. and Murray, T.F.: Differential regulation of [3H]dextrorphan binding to slide mounted rat brain sections by modulators of NMDA receptor-channel function. Soc. for Neurosci. Absts., 18, 1156, 1992.
54. Murray, T.F. and Caldwell, V.J.: Glutamate sensitive binding of [3H]dextrorphan to intact cerebellar granule cells. The Pharmacologist, 34, 134, 1992.
55. Berman, F.W. and Murray, T.F.: Characterization of the acute neurotoxicity of glutamate in primary cultures of cerebellular granule cells. Soc. for Neuroscience Absts., 19, 1775, 1993.
56. Roth, J.E., Franklin, P.H. and Murray, T.F.: Dextrorotatory opioid-induced stereotypes are correlated with high affinity [3H]dextrorphan binding in rat brain. Soc. for Neuroscience Absts., 19, 718, 1993.
57. Zhang, G., Murray, T.F. and Kelly, M.J.: Effect of estrogen on:-opioid receptor G-protein coupling in guinea-pig mediobasal hypothalamus (MBH). Soc. for Nueorscience Absts., 19, 1154, 1993.
58. Hettinger-Smith, B.D., Leid, M. and Murray T.F.: Upregulation of A1 adenosine receptors in cerebellar granule cells in response to chronic caffeine exposure. Soc. for Neuroscience Absts., 20, 1548, 1994.
59. Soderstrom, K., Moore, F.L., Franklin, P.H. and Murray, T.F.: Characterization of a cannabinoid receptor in the rough-skin newt. Soc. for Neuroscience Absts., 20, 1236, 1994.
60. Roth, J.E., Murray, T.F. and Franklin, P.H.: Regional distribution and characterization of [3H]dextrorphan binding sites in rat brain determined by quantitative autoradiography. Soc. for Neuroscience Absts,. 20, 1141, 1994.
61. Murray, T.F. and Zhao, X.: Pharmacological characterization of a P2 purinoceptor mediated behavioral seizure in the rat prepiriform cortex. FASEB J., 9, A120, 1995.
62. Hettinger-Smith, B.D., Leid, M. and Murray, T.F.: A1 adenosine receptor regulation in cerebellar granule cells. FASEB J., 9, A121, 1995.
63. Hettinger-Smith, B.D., Leid, M. and Murray, T.F.: Regulation of A1 adenosine receptor expression in cerebellar granule cells affects sensitivity to adenosine analog-induced inhibition of adenylyl cyclase. Soc. for Neurosciences Absts., 21, 1143, 1995.
64. Berman, F.W., Franklin, P.H. and Murray, T.F.: Glutamate and domoate excitotoxicity in cultured cerebellar granule neurosis composed of acute osmotically mediated and delayed neurodegenerative components. Soc. for Neurosciences Absts., 21, 1586, 1995.
65. Soderstrom, K., Choi, H., Aldrich, J.V. and Murray, T.F.: N-terminal alkylated derivatives of [D- Pro10]dynorphin A-(1-11) are high affinity partial 6-opioid receptor agonists. Soc. for Neurosciences Absts., 21, 1606, 1995.
66. Roth, J.E., Franklin, P.H., Murray, T.F. and Leid, M.: Expression of the NMDAR1 glutamate receptor subunit in COS-7 cells. Soc. for Neurosciences Absts., 21, 1837, 1995.
67. Soderstrom, K., Murray, T.F., Ketchum, S., Milligan, K., Gerwick, W., Ortega, M.J., and Salva, J.: Discovery of novel cannabinoid receptor ligands from diverse marine organisms. Prostaglandins Leukotrienes and Essential Fatty Acids, 55, Supplement 1, 7, 1996.
68. Leid, M., Peterson, V.J., Hettinger-Smith, B.D., Soderstrom, K., Murray, T.F., and Bouvier, C.: Locus coeruleus-like CATH.a cells express delta opioid receptors which are functionally coupled to inhibition of adenylyl cyclase activity. Soc. for Neuroscience Absts., 22, 70, 1996.
22 Thomas F. Murray
69. Berman, F.W. and Murray, T.F.: Domoic acid-stimulated release of glutamate and aspartate from cultured rat cerebellar granule neurons occurs via three routes: swelling-induced efflux, reversal of sodium- dependent transport and vesicular release. Soc. for Neuroscience Absts., 22, 803, 1996.
70. Hettinger-Smith, B.D., Leid M. and Murray, T.F.: A1 adenosine receptor regulation in cerebellar granule cells. Soc. for Neuroscience Absts., 22, 1043, 1996.
71. Roth, J.E., Franklin, P.H., Murray, T.F. and Leid, M.: Absence of [3H]MK-801 binding in COS-7 cells transiently expressing the NMDAR1 glutamate receptor subunit. Soc. for Neuroscience Absts., 22, 1532, 1996.
72. Evans, S.J., Moore, F.L. and Murray, T.F.: Solubilization and characterization of a [3H]corticosterone membrane receptor from amphibian brain. Soc. for Neuroscience Absts., 22, 1562, 1996.
73. Berman, F.W. and Murray, T.F. Brevetoxins induce an NMDA receptor-mediated neurotoxic response in cultured rat cerebellar granule neurons. Soc. for Neuroscience Absts., 24, 235, 1998.
74. Ishmael, J.F., Murray, T.F. and Leid, M.: The noncompetitive NMDA receptor antagonists [3H]dextrorphan binds to recombinantly expressed NMDA-type glutamate receptors. Soc. for Neuroscience Absts. 24, 574, 1998.
75. Berman, F.W. and Murray, T.F. Brevetoxins induce a neurotoxic response in cultured rat cerebellar granule neurons that is mediated by NMDA receptors. The Toxicologist, 48, 285, 1999.
76. Murray, T.F. and Berman, F.W. Brevetoxin-induced autocrine excitotoxicity is associated with manifold routes of Ca2+ influx. The Toxicologist 49, 175, 2000.
77. Li, W.I., Berman, F.W., Okino, T., Gerwick, W.H. and Murray, T.F. Antillatoxin, a neurotoxin from the cyanobacteria Lyngbya majuscula, modulates [3H]batrachotoxin A20-α-benzoate (BTX-B) binding in intact cerebellar granule cells. FASEB J. 14, A1476, 2000.
78. Li, W.I., Berman, F.W., Okino, T., Gerwick, W.H. and Murray, T.F. Antillatoxin, a novel neurotoxin from the marine cyanobacteria, Lyngbya majuscula, is a potent activator of voltage-gated Na+ channels. The Toxicologist 60, 366, 2001.
79. LePage, K.T., Murray, T.F., Ishmael, J.E., Leid, M., Low, C.M. and Traynelis, S.F. Differential binding properties of [3H]Dextrorphan and [3H]MK-801 in heterologously expressed NMDA receptors. FASEB J. 15, A225, 2001.
80. Dravid, S. and Murray, T.F. Detection of calcium permeable AMPA/kainite receptors in cerebral cortical neurons using the fluorescent probe calcium AM. FASEB J. 16, A186, 2002.
81. Bennett, M.A., Murray, T.F. and Aldrich, J.V. Design, synthesis and opioid activity of analogs of acrodyn, a novel kappa-selective ligand. FASEB J. 16, A584
82. Miller, C.C. and Murray, T.F. Cannabinioid receptor regulation of veratridine-induced calcium influx in cerebellar granule cells. Soc. for Neuroscience Absts. 27, 383.3.21, 2002.
83. Dravid, S. and Murray, T.F. Spontaneous synchronized calcium oscillations in neocortical neurons in the presence of physiological [Mg2+]: Involvement of AMPA/kainate receptors and metabotropic glutamate receptors. 27, 481.13, 2002.
84. Murray, T.F., Dravid, S. and Baden D. G. Brevetoxin exposure augments Ca 2+ oscillations in cerebrocortical neurons. The Toxicologist 61, 2002.
23 Thomas F. Murray
85. Murray, T.F. and Dravid S. Brevetoxin-induced alterations in neuronal Ca2+ dynamics and cell signaling. The Toxicologist 72, 115, 2003.
86. Dravid, S., Baden, D.G. and Murray, T.F. Brevetoxin augments NMDA receptor signaling in marine cerebrocortical neurons. The Toxicologist 72, 344, 2003.
87. Murray, T.F., Yan, X, McNeill, B., Vanderplas, M.L., Linder, J.M. and Moore, J. Labeling and functional characterization of adenosine A(2A). FASEB Journal 17:A636, Part 1 Suppl. S, 2003.
88. Murray, T.F., Baden, D.G. and Dravid, S.M. Brevetoxin-induced coincident activation of Src kinase and voltage-gated sodium channels enhances NMDA receptor signaling in neocortical neurons. Abstract No. 416. 2004 Itinerary Planner. Baltimore, MD: Society of Toxicology.
89. Murray, T.F., Baden, D.G. and Dravid, S.M. Sodium channel activation enhances Src kinase and NMDA receptor signaling in neocortical neurons. Program No. 398.13, Society for Neuroscience, 2004. Online.
90. Dravid, S.M., Lyuboslavsky, P., French, A.M., Murray, T.F. and Traynelis, S.F. Stereo-selective coupling of MK-801 block of NMDA receptors to proton-sensitive gating. Program No. 99.11, Society for Neuroscience, 2004. Online.
91. Murray, T.F., Benson, J.M., Hale, C.S. and Yan, X. Cigarette smoke inhalation in juvenile rats as an animal model for adolescent nicotine exposure. FASEB Journal 19:A1074-A1075, Part 2 Suppl. S, 2005.
92. Cao, Z. Coffield, J. Baden, D.G. and T.F. Murray. Brevetoxin augments phosphorylation of pyk2 and src in murine neocortical neurons Program No. 842.19. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2005. Online.
93. Peterson, J.H. and T.F. Murray. Brevetoxin-induced upregulation of nmda receptor function requires na+ and src tyrosine kinase Program No. 842.20. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2005. Online.
94. Cao,Z., Baden, D.G. and T.F. Murray. Brevetoxin-induced phosphorylation of Pyk2 and Src in murine neocortical neurons occurs through distinct pathways Program No. 130.12. 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online.
95. LePage, K.T., Stice, S.L. and T.F.Murray. Activation of voltage-gated sodium channels produces Ca2+ influx in human neural progenitor cell lines derived from embryonic stem cells Program No. 130.14. 2006
96. Koos, B.J., Yan, X. Z., Kruger, L., Linden, J. and T.F.Murray. Characterization of [125I] ZM 241385 binding to adenosine A2A receptors in the pineal of sheep brain. FASEB J. 20,A1216 Part 2, 2006.
97. Murray, T.F., Yan, X., Gomez, A.P., Baden, D.G., and Benson, J.M. Brevetoxin-induced neural insult in the retrosplenial cortex of mouse brain following inhalation exposure. The Toxicologist 96, 363, 2007.
98. LePage, K.T., Rainier, J.D. and Murray, T.F. Gambierol acts as a functional antagonist of neurotoxin site 5 on voltage-gated sodium channels in cerebellar granule cells. The Toxicologist 96, 364, 2007.
99. Xie, J. Peterson, J. Murray, T.F. Brevetoxin enhanced neurite growth involves voltage-gated sodium channel activation with engagement of NMDA receptors and CaM-kinase kinase FASEB Journal 21: A785-A786, 2007.
100. Murray, T.F., Xie, J., Peterson, J. and Baden D.G. Brevetoxin activation of voltage-gated sodium channels stimulates neurite outgrowth in immature cerebrocortical neurons. Program No. 34.13. 2007 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2007. Online.
24 Thomas F. Murray
101. Cao, Z., George, J., Gerwick, W.H. and Murray, T.F. Voltage-dependent sodium channel gating modifier toxins produce sodium influx in neocortical neurons. #1727 The Toxicologist 2008.
102. George, J., Cao, Z. and Murray, T.F. Brevetoxin sensitizes immature cerebrocortical neurons to NMDA receptor signaling through activation of voltage-gated sodium channels. FASEB Journal 22:721.6, 2008.
103. George, J. and Murray, T.F. Sodium channel activation modulates synchronized calcium oscillations and neuronal morphology in immature cerebrocortical neurons. FASEB J. 2009 23:946.1.
104. Jabba, S., Gerwick, W.H. and Murray, T.F. Antillatoxin, a novel lipopeptide, enhances neurite outgrowth in immature cerebrocortical neurons through activation of voltage - gated sodium channels. Program No. 807.2. 2008 Neuroscience Meeting. Washington, DC: Society for Neuroscience, 2008. Online.
105. Cao, Z., Shafer, T.J. and Murray, T.F.. Influence of pyrethroid insecticides on sodium and calcium influx in neocortical neurons. The Toxicologist, 2009.
106. Murray, T.F., Busse, E.C. and George, J. Voltage-gated sodium channel activators with differing efficacies stimulate neurite outgrowth in cerebrocortical neurons. Program No. 9.9. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009. Online.
Grant Support:
Active Support:
1. “Peptidic Ligands for κ Opioid Receptors,” NIH/NIDA (R01 NIDA). $384,421, 12/01/04-12/31/09. Jane Aldrich, Principal Investigator, Thomas F. Murray, PI-subcontract.
2. “Neurotoxins from Marine Algae and Cyanobacteria.” NIH, PHS (2 R01 GM63554). $721,671, 7/01/05- 9/30/10. William H. Gerwick, Co-Principal Investigator, Thomas F. Murray, Co-Principal Investigator.
3. “Hypoxia and the Control of Fetal Breathing Movements.” NIH, PHS (R01 HD 18478), $207,465; 12/01/05-12/31/10. Brian J. Koos, Principal Investigator, Thomas F. Murray, PI-subcontract.
4. “Peptidic Kappa Opioid Receptor Ligands as Potential Treatments for Drug Addiction” NIH/NIDA R01 DA023924-01 $505,834; 09/15/07 – 09/14/12. Jane Aldrich Principal Investigator, Thomas F. Murray, PI- subcontract.
5. “Affinity Labels for Opioid Receptors,” NIH/NIDA (R01 DA10035). $548,996, 10/01/09- 09/30/11, Jane Aldrich Principal Investigator , Thomas F. Murray, PI-subcontract.
Pending Support:
1. “Neurotoxins from Marine Algae and Cyanobacteria.” NIH, PHS (3 R01 GM63554). $1,534,340, 7/01/10- 6/30/15. William H. Gerwick, Co-Principal Investigator, Thomas F. Murray, Co-Principal Investigator.
Expired Support:
1. Pharmaceutical Manufacturers Association Research Starter Grant. “The in vivo and in vitro Modulation of Rat Brain Adenosine (A1) Receptors,” $13,000; 1/1/81 - 12/31/83. Thomas F. Murray, Principal Investigator.
25 Thomas F. Murray
2. State of Washington Initiative Measure No. 171 for Medical and Biological Research on Alcoholism. “The Role of Endogenous Adenosine in the Behavioral and Neurochemical Effects of Ethanol,” $16,356; 2/1/82 - 1/31/83. Thomas F. Murray, Principal Investigator.
3. Epilepsy Foundation of America. “An Evaluation of the Role of Endogenous Adenosine in the Regulation of Seizure Susceptibility,” $14,988; 3/1/83 - 6/30/84. Thomas F. Murray, Principal Investigator.
4. Chemical Research and Development Center, U.S. Army, Aberdeen Proving Ground, M.D. “Mathematical Modeling of the GABA Synaptic Process,” $22,916; 6/1/84 - 3/31/85. John H. Block, Principal Investigator; J. Mark Christensen and Thomas F. Murray, Co-investigators.
5. Oregon State University Research Council. “Effects of Chronic Methylxanthine Administration on Adenosine Mechanisms,” $7,500; 6/1/84 -5/31/85. Thomas F. Murray, Principal Investigator.
6. Oregon State University Environmental Health Sciences Center. “Neurochemical Mechanisms of Type II Pyrethroid Toxicity,” $14,954; 12/1/84 - 11/30/85. Thomas F. Murray, Principal Investigator.
7. Pfizer Central Research, Pfizer Inc. “Effects of Adenosine Receptor Blockers on High Affinity Choline Uptake in Rat Brain,” $19,403; 2/1/85 - 6/30/86. Thomas F. Murray, Principal Investigator.
8. “Adenosine Receptor Modulation of Seizure Susceptibility,” NINCDS, PHS (R23NS23227); $31,698; 7/1/86 - 6/30/87. Thomas F. Murray, Principal Investigator.
9. “Ontogenesis of Embryonic Chick Heart Adenosine Receptors,” American Heart Association/Oregon Affiliate; $25,850; 7/1/86 - 6/30/87. Thomas F. Murray, Principal Investigator.
10. “Oregon State University PROPHET II Implementation,” DRR, PHS (R24RR04349); $16,897;9/30/87- 9/29/88. Thomas F. Murray, Principal Investigator.
11. “Effects of Pressure on Membrane-Associated Receptors and Effector Elements,” Office of Naval Research; $46,364; 8/1/88-7/31/89. Thomas F. Murray and Joseph F. Siebenaller, Co-investigators.
12. “Adenosine Receptor Modulation of Seizure Susceptibility,” NINCDS, PHS (R29NS23227); $309,910; 7/1/87-6/30/91. Thomas F. Murray, Principal Investigator.
13. “Effects of Pressure on Membrane-Associated Receptors and Effector Elements,” Office of Naval Research; $130,300; 8/1/89-7/31/91. Thomas F. Murray, and Joseph F. Siebenaller, Co-Principal Investigators.
14. “Mechanisms of Pyrethroid Insecticide Neurotoxicology,” NIEHS, PHS (R01ES04891); $251,036; 8/1/88- 7/31/92. Thomas F. Murray, Principal Investigator.
15. “Dynorphin Analogues as 6 Opioid Receptor Antagonists,” NIDA, PHS (R01DA05195); $343,530; 9/30/89-11/31/92. Jane V. Aldrich, Principal Investigator; Gary E. DeLander and Thomas F. Murray, Co- investigators.
16. “Effects of Pressure on Membrane-Associated Receptors and Effector Elements,” Louisiana State University Subcontract; $33,798; 8/1/91-11/30/93. Joseph F. Siebenaller, Principal Investigator; Thomas F. Murray, Co-investigator.
17. “ADAMHA-Small Instrumentation Program,” NIDA, PHS (S5 DA08290A); $26,618, 9/30/92-8/31/93. Thomas F. Murray, Principal Investigator; Jane V. Aldrich, Co-investigator.
18. “Dextrorotatory Opioids as Probes for PCP Receptors,” NIDA, PHS (R01 DA07218); $259,593; 7/1/91- 6/30/95. Thomas F. Murray, Principal Investigator; Paul Franklin, Co-investigator.
26 Thomas F. Murray
19. “Dynorphin Analogues as 6 Opioid Receptor Antagonists,” NIDA, PHS (R01 DA05195); $556,385; 7/01/93-6/30/96. Jane V. Aldrich, Principal Investigator; Gary E. DeLander and Thomas F. Murray, Co- investigators.
20. “ADAMHA Research Scientist Development Award,” NIDA, PHS (K02 DA00217); $415,977; 6/1/94- 9/01/97. Thomas F. Murray, Principal Investigator.
21. “Discovery and Production of Novel Anandamide Derivatives,” The Human Frontier Science Program; $92,000; 4/1/95-3/31/97. William H. Gerwick and Thomas F. Murray, Co-Principal Investigators.
22. “Hypoxia and the Control of Fetal Breathing Movements,” NIH, PHS (R01 HD18478); $39,461; 4/1/96- 3/31/99 (Subcontract from University of California at Los Angeles). Brian J. Koos, Principal Investigator; Thomas F. Murray, Co-investigator.
23. "Screening of Drug Discovery Libraries," NIH, SBIR; $64,798; 11/01/97 - 10/31/99 (Subcontract from Bend Research, Inc.) Blair West, Principal Investigator, Thomas F. Murray, Co-Investigator.
24. “Dextrorotatory Opioids as Probes for PCP Receptors,” NIDA, PHS (R01 DA07218); $781,297; 9/30/97- 3/31/01. Thomas F. Murray, Principle Investigator; Steven Traynelis, Co-investigator.
25. “Affinity Labels for Kappa Opioid Receptors,” NIDA, PHS (R01 DA10035). $140,369; 8/1/97-7/31/00 (Subcontract from University of Maryland at Baltimore). Jane V. Aldrich, Principal Investigator; Thomas F. Murray, Co-investigator (Renewal submitted).
26. “Reactor for Generation of Compound Derivative Libraries,” SBIR, PHS, $82,311; 9/01/99 8/31/01. Thomas F. Murray and Blair West, Co-Principal Investigators.
27. "Drug Discovery and Biodiversity Among the Maya of Mexico," NIH, PHS, $484,330; 8/1/98 - 7/31/03. Brent Berlin, Principal Investigator; Thomas F. Murray, David J. Puett, Raghubir P. Sharma, Co- Investigators.
28. “Hypoxia and the Control of Fetal Breathing Movements.” NIH, PHS (R01 HD 18478), $74,269; 12/01/00-12/31/03. Brian J. Koos, Principal Investigator, Thomas F. Murray, Co-Investigator.
29. “Three Dimensional Animations of Signal Transduction Mechanisms,” USDA Higher Education Challenge Grants Program; 9/1/02-8/30/03; $99,999. James N. Moore, Stephen J. Lewis and Thomas F. Murray, Co-Principal Investigators.
30. “Neurotoxins from Marine Algae and Cyanobacteria.” NIH, PHS (2 R01 GM 63554). $539,129, 7/01/01- 6/30/05. William H. Gerwick, Co-Principal Investigator, Thomas F. Murray, Co-Principal Investigator.
31. “Inhibition of Endotoxin with Adenosine Receptor Agonists,” Grayson-Jockey Club, 04/01/04 – 03/31/06. Thomas F. Murray, Principal Investigator; James Moore, Co-Investigator.
27